Avidity Biosciences News

PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 21:58

Bank of America Predicts up to ~200% Surge for These 2 'Strong Buy' Stocks

Yahoo FinanceMay 19 21:03

Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing

Michael F MacLean, Chief Financial Officer, on May 14, 2024, sold 75,000 shares in Avidity Biosciences (RNA) for $2,121,045. Following the Form 4 filing with the SEC, MacLean has control over a total

MT NewswiresMay 17 15:24

Avidity Biosciences(RNA.US) Officer Sells US$2.12 Million in Common Stock

$Avidity Biosciences(RNA.US)$ Officer MacLean Michael F sold 75,000 shares of common stock on May 14, 2024 at an average price of $28.2806 for a total value of $2.12 million.Source: Announcement What

Futu NewsMay 17 07:05

Avidity Biosciences Announces Appointment of Simona Skerjanec to Bd of Directors

Avidity Biosciences Announces Appointment of Simona Skerjanec to Bd of Directors

Dow JonesMay 15 21:01

Form 144 | Avidity Biosciences(RNA.US) Officer Proposes to Sell 1.95 Million in Common Stocks

SEC FILLINGS DISCLOSED/ May 14, $Avidity Biosciences(RNA.US)$ Officer MICHAEL MACLEAN intends to sell 75,000 shares of its common stock on May 14, with a total market value of approximately $1.95 mill

Futu NewsMay 15 04:28

Vicore Expands and Strengthens Its Board of Directors

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of

AccesswireMay 14 14:20

Avidity Biosciences: Strong Buy on Promising Trials and Solid Financials

TipRanksMay 13 18:22

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow JonesMay 10 22:20

Avidity Biosciences Price Target Maintained With a $35.00/Share by Needham

Avidity Biosciences Price Target Maintained With a $35.00/Share by Needham

Dow JonesMay 10 19:10

Needham: Reiterates Avidity Biosciences (RNA.US) rating and adjusted from buy to buy rating, target price is $35.00.

Needham: Reiterates Avidity Biosciences (RNA.US) rating and adjusted from buy to buy rating, target price is $35.00.

Zhitong FinanceMay 10 19:03

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.

BenzingaMay 10 19:00

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA) and Curaleaf Holdings (OtherCURLF)

TipRanksMay 10 17:30

HHS Panel to Vote in Nov. on DMD Screening for Newborns

Seeking AlphaMay 10 06:44

Avidity Biosciences Files Automatic Mixed Shelf

Seeking AlphaMay 10 04:43

Avidity Biosciences | 10-Q: Quarterly report

Futu NewsMay 10 04:21 · Announcements

Avidity Biosciences 1Q Loss/Shr 79c >RNA

Avidity Biosciences 1Q Loss/Shr 79c >RNA

Dow JonesMay 10 04:05

Press Release: Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights PR Newswire SAN DIEGO, May 9, 2024 Initiation of global Phase 3 HARBOR(TM) trial for del-desiran (AOC 1001) in

Dow JonesMay 10 04:05

Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancements

TipRanksMay 9 17:17

Avidity Biosciences to Participate in Upcoming Investor Conference

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Con

PR NewswireMay 9 04:05